Bill

Bill > S808


MA S808

MA S808
Relative to cancer patient access to biomarker testing to provide appropriate therapy


summary

Introduced
03/29/2021
In Committee
03/29/2021
Crossed Over
Passed
Dead
12/31/2022

Introduced Session

192nd General Court

Bill Summary

For legislation relative to cancer patient access to biomarker testing to provide appropriate therapy. Health Care Financing.

AI Summary

This bill prohibits health insurance plans in Massachusetts from requiring prior authorization for biomarker testing for individuals with advanced or metastatic stage 3 or 4 cancer, as well as for testing related to cancer progression or recurrence. Biomarker testing refers to diagnostic tests of a cancer patient's tissue, blood, or other bodily fluids to identify DNA or RNA alterations that can help guide the patient's treatment. The bill applies to various types of health insurance plans, including those offered by the state's Group Insurance Commission, MassHealth (the state's Medicaid program), and private insurers.

Committee Categories

Health and Social Services

Sponsors (2)

Last Action

Accompanied a study order, see S2917 (on 06/09/2022)

bill text


bill summary

Loading...

bill summary

Loading...

bill summary

Loading...